Takeda Partners with Sosei Heptares on GPCR Targets
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)
Published: 7 Aug-2019
DOI: 10.3833/pdr.v2019.i8.2448 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Reflecting its therapeutic focus on gastroenterology, Takeda Pharmaceutical has agreed to a multi-target alliance with Sosei Heptares to discover, develop and commercialise therapeutics that modulate G protein-coupled receptors (GPCR) for up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS